Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 16/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 16/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71015 | 0.85 | TTR (0.52) | AKR1C3LCKFYNTTR | |
| SCHEMBL30162908 | 0.85 | TTR (0.52) | AKR1C3LCKFYNTTR | |
| SCHEMBL27958984 | 0.84 | AKR1C3 (0.55) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL2447213 | 0.84 | TTR (0.47) | AKR1C3AKR1C2AKR1C4AKR1C1NPC1 | |
| Hydrochloric Acid SCHEMBL28568371 | 0.83 | KDM4E (0.50) | AKR1C3LCKFYNTTR | |
| Hydrochloric Acid SCHEMBL7704938 | 0.83 | KDM4E (0.50) | AKR1C3LCKFYNTTR | |
| SCHEMBL28743014 | 0.82 | CYP1A2 (0.51) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL7823608 | 0.81 | CDC25A (0.59) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL9016382 | 0.81 | MYC (0.49) | LCKFYNSMN1; SMN2TTR | |
| SCHEMBL15855843 | 0.80 | PARP1 (0.47) | AKR1C3LCKFYNSMN1; SMN2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103864702-A | Method for preparing quinazolinone in water phase through microwave catalysis | UNIV FUJIAN MEDICAL | 2014-06-18 | — | — | CN | disclosed |
| CN-103819414-A | Method for preparing quinazolone compound by catalysis in water phase | UNIV FUJIAN MEDICAL | 2014-05-28 | — | — | CN | disclosed |
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2176223-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| CN-101687797-A | Malonamide derivatives with antithrombotic activity | SANOFI AVENTIS | 2010-03-31 | — | — | CN | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | AKR1C3 628/4885AKR1C2 451/4885AKR1B10 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.